Puma Biotechnology Inc

NAS:PBYI (USA)  
$ 6.51 +0.05 (+0.77%) 02:50 PM EST
80.75
P/B:
7.88
Market Cap:
$ 307.31M
Enterprise V:
$ 334.50M
Volume:
422.41K
Avg Vol (2M):
538.14K
Volume:
422.41K
Avg Vol (2M):
538.14K

Business Description

Description
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Name Current Vs Industry Vs History
Cash-To-Debt 0.76
Equity-to-Asset 0.19
Debt-to-Equity 2.9
Debt-to-EBITDA 4.01
Interest Coverage 2.15
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.46
Distress
Grey
Safe
Beneish M-Score -2.68
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 50.34
9-Day RSI 55.28
14-Day RSI 57.84
6-1 Month Momentum % 31.27
12-1 Month Momentum % 23.92

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.86
Quick Ratio 1.78
Cash Ratio 1.26
Days Inventory 35.95
Days Sales Outstanding 50.91
Days Payable 56.62

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.7
Shareholder Yield % 0.82

Financials (Next Earnings Date:2024-02-29)

PBYI's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PBYI

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Puma Biotechnology Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 229.134
EPS (TTM) ($) 0.08
Beta 1.34
Volatility % 78.62
14-Day RSI 57.84
14-Day ATR ($) 0.54445
20-Day SMA ($) 6.01575
12-1 Month Momentum % 23.92
52-Week Range ($) 2.13 - 7.73
Shares Outstanding (Mil) 47.57

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Puma Biotechnology Inc Filings

Filing Date Document Date Form
No Filing Data

Puma Biotechnology Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Puma Biotechnology Inc Frequently Asked Questions

What is Puma Biotechnology Inc(PBYI)'s stock price today?
The current price of PBYI is $6.51. The 52 week high of PBYI is $7.73 and 52 week low is $2.13.
When is next earnings date of Puma Biotechnology Inc(PBYI)?
The next earnings date of Puma Biotechnology Inc(PBYI) is 2024-02-29.
Does Puma Biotechnology Inc(PBYI) pay dividends? If so, how much?
Puma Biotechnology Inc(PBYI) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1